Omnicell, Inc. (NASDAQ:OMCL) Ratings Summary on Jun 27, 2018

June 27, 2018 - By Matthew Medley

Omnicell, Inc. (NASDAQ:OMCL) Corporate Logo
During 2018 Q1 the big money sentiment decreased to 1.03. That’s change of 0.09, from 2017Q4’s 1.12. 26 investors sold all, 69 reduced holdings as Omnicell, Inc. ratio is negative. 68 increased holdings while 30 funds bought holdings. Funds hold 37.13 million shares thus 0.68% less from 2017Q4’s 37.38 million shares.
Reilly Financial Advsr Ltd Liability Com owns 177 shs. 37,444 are held by Teachers Retirement Of The State Of Kentucky. Wells Fargo And Co Mn holds 294,162 shs. First Interstate Savings Bank has 386 shs. State Board Of Administration Of Florida Retirement has invested 0% in Omnicell, Inc. (NASDAQ:OMCL). Fifth Third National Bank & Trust holds 0% in Omnicell, Inc. (NASDAQ:OMCL) or 51 shs. Scout Inc holds 170,650 shs. Needham Mngmt Ltd holds 10,500 shs. Captrust Fincl Advsr owns 33 shs. Barclays Public Ltd Com stated it has 0% of its capital in Omnicell, Inc. (NASDAQ:OMCL). Northwestern Mutual Wealth Mngmt invested in 237 shs. Ameritas Inv Ptnrs Incorporated holds 0.01% or 3,074 shs in its capital. Schwab Charles Inv Management holds 184,939 shs. Savings Bank Of Montreal Can owns 1,702 shs. Moreover, Asset Mngmt has 0% invested in Omnicell, Inc. (NASDAQ:OMCL).

Omnicell, Inc. had 12 insider sales and 0 insider purchases since March 6, 2018. This’s net activity of $5.06 million. On Friday, June 15 439 shs were sold by LIPPS RANDALL A, worth $22,828. The insider Ngo Nhat H sold 4,114 shs worth $213,946. JOHNSTON DAN S also sold $507,248 worth of Omnicell, Inc. (NASDAQ:OMCL) on Monday, April 16. On Thursday, March 15 $25,544 worth of stock was sold by PETERSMEYER GARY S. Seim Robin Gene sold $751,584 worth of Omnicell, Inc. (NASDAQ:OMCL) on Monday, June 4. On Tuesday, June 5 DREW J CHRISTOPHER also sold $471,778 worth of Omnicell, Inc. (NASDAQ:OMCL).

Omnicell, Inc. (NASDAQ:OMCL) Ratings Coverage

In total 4 analysts cover Omnicell (NASDAQ:OMCL). “Buy” rating has 2, “Sell” are 0, while 2 are “Hold”. (NASDAQ:OMCL) has 50% bullish analysts. 5 are the (NASDAQ:OMCL)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Thursday, February 1 the firm has “Buy” rating given by Cantor Fitzgerald. On Monday, January 29 the firm earned “Buy” rating by Oppenheimer. In Friday, February 2 report PiperJaffray maintained the stock with “Neutral” rating. On Friday, February 2 the firm earned “Hold” rating by Craig Hallum. On Thursday, April 26 the company was maintained by Cantor Fitzgerald. Listed here are Omnicell, Inc. (NASDAQ:OMCL) PTs and latest ratings.

26/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $63.0000 Maintain
02/02/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Neutral Old Target: $38 New Target: $44 Maintain
02/02/2018 Broker: Craig Hallum Rating: Hold Downgrade
01/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $63.0 Maintain
29/01/2018 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain

The stock decreased 0.57% or $0.3 during the last trading session, hitting $52.6.Omnicell, Inc. has volume of 35,039 shares. Since June 27, 2017 OMCL has risen 10.62% and is uptrending. OMCL underperformed the S&P500 by 1.95%.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide.The firm is worth $2.05 billion. The firm operates through two divisions, Automation and Analytics, and Medication Adherence.61.66 is the P/E ratio. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Savvy Mobile Medication Workstation, which provides a platform for hospital information systems.

Another two news for Omnicell, Inc. (NASDAQ:OMCL) were recently brought out by: on June 12, 2018 with title “STOMPP Study Demonstrates Multimed Packaging Improves Medication Adherence”. The other‘s article was titled “Robotics developers are ripe for investment, says Innovation Works CEO Rich Lunak” and brought out on June 20, 2018.

Omnicell, Inc. (NASDAQ:OMCL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.